291 related articles for article (PubMed ID: 24833203)
1. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Yusuf AA; Howell BL; Powers CA; St Peter WL
Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
[TBL] [Abstract][Full Text] [Related]
2. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
3. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
[TBL] [Abstract][Full Text] [Related]
4. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432
[TBL] [Abstract][Full Text] [Related]
5. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006.
St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA
Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318
[TBL] [Abstract][Full Text] [Related]
7. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
St Peter WL; Wazny LD; Weinhandl ED
Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
9. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
10. Managing oral phosphate binder medication expenditures within the Medicare bundled end-stage renal disease prospective payment system: economic implications for large U.S. dialysis organizations.
Park H; Rascati KL; Keith MS
J Manag Care Spec Pharm; 2015 Jun; 21(6):507-14. PubMed ID: 26011552
[TBL] [Abstract][Full Text] [Related]
11. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
12. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
Fukagawa M; Fukuma S; Onishi Y; Yamaguchi T; Hasegawa T; Akizawa T; Kurokawa K; Fukuhara S
Clin J Am Soc Nephrol; 2012 Sep; 7(9):1473-80. PubMed ID: 22822017
[TBL] [Abstract][Full Text] [Related]
13. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
Belozeroff V; Lee A; Tseng S; Chiroli S; Campbell JD
J Med Econ; 2013 Sep; 16(9):1154-62. PubMed ID: 23869940
[TBL] [Abstract][Full Text] [Related]
14. Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States.
Hall R; Platt A; Wilson J; Ephraim PL; Hwang AS; Chen A; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1603-1613. PubMed ID: 33046525
[TBL] [Abstract][Full Text] [Related]
15. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
16. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
17. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
[TBL] [Abstract][Full Text] [Related]
18. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
19. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
